Loading…

Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2014-10, Vol.6 (260), p.260ra148-260ra148
Main Authors: Pan, Ying, Volkmer, Jens-Peter, Mach, Kathleen E, Rouse, Robert V, Liu, Jen-Jane, Sahoo, Debashis, Chang, Timothy C, Metzner, Thomas J, Kang, Lei, van de Rijn, Matt, Skinner, Eila C, Gambhir, Sanjiv S, Weissman, Irving L, Liao, Joseph C
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3
cites cdi_FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3
container_end_page 260ra148
container_issue 260
container_start_page 260ra148
container_title Science translational medicine
container_volume 6
creator Pan, Ying
Volkmer, Jens-Peter
Mach, Kathleen E
Rouse, Robert V
Liu, Jen-Jane
Sahoo, Debashis
Chang, Timothy C
Metzner, Thomas J
Kang, Lei
van de Rijn, Matt
Skinner, Eila C
Gambhir, Sanjiv S
Weissman, Irving L
Liao, Joseph C
description A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.
doi_str_mv 10.1126/scitranslmed.3009457
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1619314792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1619314792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EolD4A4S8ZJPiV-x4iUp5qRIbWFuOPSlBSVzsZNG_J1FbxGpGc--d0RyEbihZUMrkfXJ1H22Xmhb8ghOiRa5O0AXVQmaSCXb613MxQ5cpfRMiC57LczRjOc9zqYsL9LbqfEgubGuH29CAGxobcd3aTd1tcKjw19DaDpeN9R4idrZzYxnSpFq8fBQK266vy-B3V-issk2C60Odo8-n1cfyJVu_P78uH9aZ44r3GZU-F1IwXQhttSglgFMlcEYkEPBlAUoCLeUkKah8TrkntvCaMEcqavkc3e33bmP4GSD1pq2Tg6axHYQhGSqp5lQozUar2FtdDClFqMw2jr_FnaHETBTNf4rmQHGM3R4uDOU0P4aO2PgvsclxLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1619314792</pqid></control><display><type>article</type><title>Endoscopic molecular imaging of human bladder cancer using a CD47 antibody</title><source>Alma/SFX Local Collection</source><creator>Pan, Ying ; Volkmer, Jens-Peter ; Mach, Kathleen E ; Rouse, Robert V ; Liu, Jen-Jane ; Sahoo, Debashis ; Chang, Timothy C ; Metzner, Thomas J ; Kang, Lei ; van de Rijn, Matt ; Skinner, Eila C ; Gambhir, Sanjiv S ; Weissman, Irving L ; Liao, Joseph C</creator><creatorcontrib>Pan, Ying ; Volkmer, Jens-Peter ; Mach, Kathleen E ; Rouse, Robert V ; Liu, Jen-Jane ; Sahoo, Debashis ; Chang, Timothy C ; Metzner, Thomas J ; Kang, Lei ; van de Rijn, Matt ; Skinner, Eila C ; Gambhir, Sanjiv S ; Weissman, Irving L ; Liao, Joseph C</creatorcontrib><description>A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.</description><identifier>ISSN: 1946-6234</identifier><identifier>EISSN: 1946-6242</identifier><identifier>DOI: 10.1126/scitranslmed.3009457</identifier><identifier>PMID: 25355698</identifier><language>eng</language><publisher>United States</publisher><subject>CD47 Antigen - genetics ; CD47 Antigen - immunology ; Endoscopy ; Humans ; RNA, Messenger - genetics ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - immunology ; Urinary Bladder Neoplasms - surgery</subject><ispartof>Science translational medicine, 2014-10, Vol.6 (260), p.260ra148-260ra148</ispartof><rights>Copyright © 2014, American Association for the Advancement of Science.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3</citedby><cites>FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25355698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Ying</creatorcontrib><creatorcontrib>Volkmer, Jens-Peter</creatorcontrib><creatorcontrib>Mach, Kathleen E</creatorcontrib><creatorcontrib>Rouse, Robert V</creatorcontrib><creatorcontrib>Liu, Jen-Jane</creatorcontrib><creatorcontrib>Sahoo, Debashis</creatorcontrib><creatorcontrib>Chang, Timothy C</creatorcontrib><creatorcontrib>Metzner, Thomas J</creatorcontrib><creatorcontrib>Kang, Lei</creatorcontrib><creatorcontrib>van de Rijn, Matt</creatorcontrib><creatorcontrib>Skinner, Eila C</creatorcontrib><creatorcontrib>Gambhir, Sanjiv S</creatorcontrib><creatorcontrib>Weissman, Irving L</creatorcontrib><creatorcontrib>Liao, Joseph C</creatorcontrib><title>Endoscopic molecular imaging of human bladder cancer using a CD47 antibody</title><title>Science translational medicine</title><addtitle>Sci Transl Med</addtitle><description>A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.</description><subject>CD47 Antigen - genetics</subject><subject>CD47 Antigen - immunology</subject><subject>Endoscopy</subject><subject>Humans</subject><subject>RNA, Messenger - genetics</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - immunology</subject><subject>Urinary Bladder Neoplasms - surgery</subject><issn>1946-6234</issn><issn>1946-6242</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRS0EolD4A4S8ZJPiV-x4iUp5qRIbWFuOPSlBSVzsZNG_J1FbxGpGc--d0RyEbihZUMrkfXJ1H22Xmhb8ghOiRa5O0AXVQmaSCXb613MxQ5cpfRMiC57LczRjOc9zqYsL9LbqfEgubGuH29CAGxobcd3aTd1tcKjw19DaDpeN9R4idrZzYxnSpFq8fBQK266vy-B3V-issk2C60Odo8-n1cfyJVu_P78uH9aZ44r3GZU-F1IwXQhttSglgFMlcEYkEPBlAUoCLeUkKah8TrkntvCaMEcqavkc3e33bmP4GSD1pq2Tg6axHYQhGSqp5lQozUar2FtdDClFqMw2jr_FnaHETBTNf4rmQHGM3R4uDOU0P4aO2PgvsclxLg</recordid><startdate>20141029</startdate><enddate>20141029</enddate><creator>Pan, Ying</creator><creator>Volkmer, Jens-Peter</creator><creator>Mach, Kathleen E</creator><creator>Rouse, Robert V</creator><creator>Liu, Jen-Jane</creator><creator>Sahoo, Debashis</creator><creator>Chang, Timothy C</creator><creator>Metzner, Thomas J</creator><creator>Kang, Lei</creator><creator>van de Rijn, Matt</creator><creator>Skinner, Eila C</creator><creator>Gambhir, Sanjiv S</creator><creator>Weissman, Irving L</creator><creator>Liao, Joseph C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141029</creationdate><title>Endoscopic molecular imaging of human bladder cancer using a CD47 antibody</title><author>Pan, Ying ; Volkmer, Jens-Peter ; Mach, Kathleen E ; Rouse, Robert V ; Liu, Jen-Jane ; Sahoo, Debashis ; Chang, Timothy C ; Metzner, Thomas J ; Kang, Lei ; van de Rijn, Matt ; Skinner, Eila C ; Gambhir, Sanjiv S ; Weissman, Irving L ; Liao, Joseph C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>CD47 Antigen - genetics</topic><topic>CD47 Antigen - immunology</topic><topic>Endoscopy</topic><topic>Humans</topic><topic>RNA, Messenger - genetics</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - immunology</topic><topic>Urinary Bladder Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Ying</creatorcontrib><creatorcontrib>Volkmer, Jens-Peter</creatorcontrib><creatorcontrib>Mach, Kathleen E</creatorcontrib><creatorcontrib>Rouse, Robert V</creatorcontrib><creatorcontrib>Liu, Jen-Jane</creatorcontrib><creatorcontrib>Sahoo, Debashis</creatorcontrib><creatorcontrib>Chang, Timothy C</creatorcontrib><creatorcontrib>Metzner, Thomas J</creatorcontrib><creatorcontrib>Kang, Lei</creatorcontrib><creatorcontrib>van de Rijn, Matt</creatorcontrib><creatorcontrib>Skinner, Eila C</creatorcontrib><creatorcontrib>Gambhir, Sanjiv S</creatorcontrib><creatorcontrib>Weissman, Irving L</creatorcontrib><creatorcontrib>Liao, Joseph C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Science translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Ying</au><au>Volkmer, Jens-Peter</au><au>Mach, Kathleen E</au><au>Rouse, Robert V</au><au>Liu, Jen-Jane</au><au>Sahoo, Debashis</au><au>Chang, Timothy C</au><au>Metzner, Thomas J</au><au>Kang, Lei</au><au>van de Rijn, Matt</au><au>Skinner, Eila C</au><au>Gambhir, Sanjiv S</au><au>Weissman, Irving L</au><au>Liao, Joseph C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endoscopic molecular imaging of human bladder cancer using a CD47 antibody</atitle><jtitle>Science translational medicine</jtitle><addtitle>Sci Transl Med</addtitle><date>2014-10-29</date><risdate>2014</risdate><volume>6</volume><issue>260</issue><spage>260ra148</spage><epage>260ra148</epage><pages>260ra148-260ra148</pages><issn>1946-6234</issn><eissn>1946-6242</eissn><abstract>A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.</abstract><cop>United States</cop><pmid>25355698</pmid><doi>10.1126/scitranslmed.3009457</doi></addata></record>
fulltext fulltext
identifier ISSN: 1946-6234
ispartof Science translational medicine, 2014-10, Vol.6 (260), p.260ra148-260ra148
issn 1946-6234
1946-6242
language eng
recordid cdi_proquest_miscellaneous_1619314792
source Alma/SFX Local Collection
subjects CD47 Antigen - genetics
CD47 Antigen - immunology
Endoscopy
Humans
RNA, Messenger - genetics
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - surgery
title Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A04%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endoscopic%20molecular%20imaging%20of%20human%20bladder%20cancer%20using%20a%20CD47%20antibody&rft.jtitle=Science%20translational%20medicine&rft.au=Pan,%20Ying&rft.date=2014-10-29&rft.volume=6&rft.issue=260&rft.spage=260ra148&rft.epage=260ra148&rft.pages=260ra148-260ra148&rft.issn=1946-6234&rft.eissn=1946-6242&rft_id=info:doi/10.1126/scitranslmed.3009457&rft_dat=%3Cproquest_cross%3E1619314792%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c373t-16d546429849a94b6eec7be3206e0edb8e76e1b694b67efd513d0a8d902c0f1a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1619314792&rft_id=info:pmid/25355698&rfr_iscdi=true